Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications
Identifieur interne : 001782 ( Istex/Corpus ); précédent : 001781; suivant : 001783Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications
Auteurs : Fredricka C. Martin ; Anh Thu Le ; Adrian HandforthSource :
- Movement Disorders [ 0885-3185 ] ; 2005-03.
English descriptors
- KwdEn :
Abstract
No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20‐minute epochs. The motion power over the tremor frequency bandwidth (8–12 Hz in rats; 10–16 Hz in mice) was divided by the motion power over the full motion frequency range (0–15 Hz in rats; 0–34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline‐induced tremor. We propose that, with this methodology, harmaline‐induced tremor may be useful as a preclinical method to identify potential medications for ET. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20331
Links to Exploration step
ISTEX:E60E297F230EE50CE9DA6B197C3594D6C2408312Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title><author><name sortKey="Martin, Fredricka C" sort="Martin, Fredricka C" uniqKey="Martin F" first="Fredricka C." last="Martin">Fredricka C. Martin</name><affiliation><mods:affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Thu Le, Anh" sort="Thu Le, Anh" uniqKey="Thu Le A" first="Anh" last="Thu Le">Anh Thu Le</name><affiliation><mods:affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Handforth, Adrian" sort="Handforth, Adrian" uniqKey="Handforth A" first="Adrian" last="Handforth">Adrian Handforth</name><affiliation><mods:affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E60E297F230EE50CE9DA6B197C3594D6C2408312</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20331</idno><idno type="url">https://api.istex.fr/document/E60E297F230EE50CE9DA6B197C3594D6C2408312/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001782</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title><author><name sortKey="Martin, Fredricka C" sort="Martin, Fredricka C" uniqKey="Martin F" first="Fredricka C." last="Martin">Fredricka C. Martin</name><affiliation><mods:affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Thu Le, Anh" sort="Thu Le, Anh" uniqKey="Thu Le A" first="Anh" last="Thu Le">Anh Thu Le</name><affiliation><mods:affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Handforth, Adrian" sort="Handforth, Adrian" uniqKey="Handforth A" first="Adrian" last="Handforth">Adrian Handforth</name><affiliation><mods:affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-03">2005-03</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="298">298</biblScope><biblScope unit="page" to="305">305</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E60E297F230EE50CE9DA6B197C3594D6C2408312</idno><idno type="DOI">10.1002/mds.20331</idno><idno type="ArticleID">MDS20331</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>essential tremor</term><term>ethanol</term><term>harmaline</term><term>octanol</term><term>propranolol</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20‐minute epochs. The motion power over the tremor frequency bandwidth (8–12 Hz in rats; 10–16 Hz in mice) was divided by the motion power over the full motion frequency range (0–15 Hz in rats; 0–34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline‐induced tremor. We propose that, with this methodology, harmaline‐induced tremor may be useful as a preclinical method to identify potential medications for ET. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Fredricka C. Martin PhD</name><affiliations><json:string>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>Anh Thu Le BS</name><affiliations><json:string>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>Adrian Handforth MD</name><affiliations><json:string>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</json:string><json:string>Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>essential tremor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>harmaline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>propranolol</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>ethanol</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>octanol</value></json:item></subject><language><json:string>eng</json:string></language><abstract>No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20‐minute epochs. The motion power over the tremor frequency bandwidth (8–12 Hz in rats; 10–16 Hz in mice) was divided by the motion power over the full motion frequency range (0–15 Hz in rats; 0–34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline‐induced tremor. We propose that, with this methodology, harmaline‐induced tremor may be useful as a preclinical method to identify potential medications for ET. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>5.998</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1049</abstractCharCount><pdfWordCount>4030</pdfWordCount><pdfCharCount>24475</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>164</abstractWordCount></qualityIndicators><title>Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title><genre><json:string>Serial article</json:string></genre><host><volume>20</volume><pages><total>8</total><last>305</last><first>298</first></pages><issn><json:string>0885-3185</json:string></issn><issue>3</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/mds.20331</json:string></doi><id>E60E297F230EE50CE9DA6B197C3594D6C2408312</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/E60E297F230EE50CE9DA6B197C3594D6C2408312/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/E60E297F230EE50CE9DA6B197C3594D6C2408312/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E60E297F230EE50CE9DA6B197C3594D6C2408312/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2005</date></publicationStmt><notesStmt><note>Department of Veterans Affairs</note><note>Elan Pharmaceuticals, Inc.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title><author><persName><forename type="first">Fredricka C.</forename><surname>Martin</surname><roleName type="degree">PhD</roleName></persName><note type="correspondence"><p>Correspondence: Veterans Affairs Greater Los Angeles Healthcare System, 11301 Wilshire Blvd., Bldg. 114, Room 226, Los Angeles, CA 90073</p></note><affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">Anh</forename><surname>Thu Le</surname><roleName type="degree">BS</roleName></persName><affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation></author><author><persName><forename type="first">Adrian</forename><surname>Handforth</surname><roleName type="degree">MD</roleName></persName><affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation><affiliation>Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-03"></date><biblScope unit="vol">20</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="298">298</biblScope><biblScope unit="page" to="305">305</biblScope></imprint></monogr><idno type="istex">E60E297F230EE50CE9DA6B197C3594D6C2408312</idno><idno type="DOI">10.1002/mds.20331</idno><idno type="ArticleID">MDS20331</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2005</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="fr"><p>No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20‐minute epochs. The motion power over the tremor frequency bandwidth (8–12 Hz in rats; 10–16 Hz in mice) was divided by the motion power over the full motion frequency range (0–15 Hz in rats; 0–34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline‐induced tremor. We propose that, with this methodology, harmaline‐induced tremor may be useful as a preclinical method to identify potential medications for ET. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>essential tremor</term></item><item><term>harmaline</term></item><item><term>propranolol</term></item><item><term>ethanol</term></item><item><term>octanol</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-08-13">Received</change><change when="2004-04-05">Registration</change><change when="2005-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/E60E297F230EE50CE9DA6B197C3594D6C2408312/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi origin="wiley" registered="yes">10.1002/mds.v20:3</doi><numberingGroup><numbering type="journalVolume" number="20">20</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2005-03">March 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="40" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20331</doi><idGroup><id type="unit" value="MDS20331"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2003-08-13"></event><event type="manuscriptRevised" date="2004-03-24"></event><event type="manuscriptAccepted" date="2004-04-05"></event><event type="firstOnline" date="2004-12-03"></event><event type="publishedOnlineFinalForm" date="2005-03-09"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2004-12-03"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText mathml2tex" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">298</numbering><numbering type="pageLast">305</numbering></numberingGroup><correspondenceTo>Veterans Affairs Greater Los Angeles Healthcare System, 11301 Wilshire Blvd., Bldg. 114, Room 226, Los Angeles, CA 90073</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20331.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="5"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="29"></count><count type="wordTotal" number="4392"></count></countGroup><titleGroup><title type="main" xml:lang="en">Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title><title type="short" xml:lang="en">Harmaline‐Induced Tremor as a Model</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Fredricka C.</givenNames><familyName>Martin</familyName><degrees>PhD</degrees></personName><contactDetails><email>fredricka.martin@med.va.gov</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anh</givenNames><familyName>Thu Le</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Adrian</givenNames><familyName>Handforth</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">essential tremor</keyword><keyword xml:id="kwd2">harmaline</keyword><keyword xml:id="kwd3">propranolol</keyword><keyword xml:id="kwd4">ethanol</keyword><keyword xml:id="kwd5">octanol</keyword></keywordGroup><fundingInfo><fundingAgency>Department of Veterans Affairs</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Elan Pharmaceuticals, Inc.</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="fr"><title type="main">Abstract</title><p>No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20‐minute epochs. The motion power over the tremor frequency bandwidth (8–12 Hz in rats; 10–16 Hz in mice) was divided by the motion power over the full motion frequency range (0–15 Hz in rats; 0–34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline‐induced tremor. We propose that, with this methodology, harmaline‐induced tremor may be useful as a preclinical method to identify potential medications for ET. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Harmaline‐Induced Tremor as a Model</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications</title></titleInfo><name type="personal"><namePart type="given">Fredricka C.</namePart><namePart type="family">Martin</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation><description>Correspondence: Veterans Affairs Greater Los Angeles Healthcare System, 11301 Wilshire Blvd., Bldg. 114, Room 226, Los Angeles, CA 90073</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anh</namePart><namePart type="family">Thu Le</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Adrian</namePart><namePart type="family">Handforth</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Research Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation><affiliation>Neurology Service, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-03</dateIssued><dateCaptured encoding="w3cdtf">2003-08-13</dateCaptured><dateValid encoding="w3cdtf">2004-04-05</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">5</extent><extent unit="references">29</extent><extent unit="words">4392</extent></physicalDescription><abstract lang="fr">No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti‐ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20‐minute epochs. The motion power over the tremor frequency bandwidth (8–12 Hz in rats; 10–16 Hz in mice) was divided by the motion power over the full motion frequency range (0–15 Hz in rats; 0–34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline‐induced tremor. We propose that, with this methodology, harmaline‐induced tremor may be useful as a preclinical method to identify potential medications for ET. © 2004 Movement Disorder Society</abstract><note type="funding">Department of Veterans Affairs</note><note type="funding">Elan Pharmaceuticals, Inc.</note><subject lang="en"><genre>Keywords</genre><topic>essential tremor</topic><topic>harmaline</topic><topic>propranolol</topic><topic>ethanol</topic><topic>octanol</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>298</start><end>305</end><total>8</total></extent></part></relatedItem><identifier type="istex">E60E297F230EE50CE9DA6B197C3594D6C2408312</identifier><identifier type="DOI">10.1002/mds.20331</identifier><identifier type="ArticleID">MDS20331</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001782 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001782 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E60E297F230EE50CE9DA6B197C3594D6C2408312
|texte= Harmaline‐induced tremor as a potential preclinical screening method for essential tremor medications
}}
| This area was generated with Dilib version V0.6.23. |  |